Skip to main content

Mintz Advises ArriVent Biopharma in $155M Series B Financing

BOSTON – Mintz represented ArriVent Biopharma, Inc, a Pennsylvania-based company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, in its $155 Million Series B financing.

Proceeds from the financing will be used to support pivotal Phase 3 and additional studies with ArriVent’s lead product candidate furmonertinib – a highly brain penetrant, mutant-specific EGFR kinase inhibitor – as well as the continued expansion of its pipeline.

The financing was led by Sofinnova Investments and General Catalyst, and had participation from Catalio Capital Management, HBM Healthcare Investments, Shanghai Healthcare Capital, Sequoia China, AIHC Capital, Terra Magnum Capital Partners, Unicorn Capital Partners Limited, and Infinitum Asset Management.

The Mintz team acting for ArriVent was led by Member Ed C. Pease and Private Equity Co-Chair Matthew T. Simpson.

Mintz is one of the leading law firms to the life sciences industry. Our industry-focused team advises thousands of businesses and other organizations across the sector’s ecosystem—from start-ups and emerging growth companies to global public companies as well as venture capital firms, investment banks, research and academic institutions. Our work for these clients encompasses intellectual property, transactional, regulatory, litigation, employment, real estate and other matters. Embedded in the global life sciences ecosystem for decades, we provide industry leaders with practical solutions to business-critical challenges, helping them achieve their strategic and business goals.

  • Transactions for industry clients, include public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings
  • Advise on the complete spectrum of FDA regulations, from clinical trials through product launch and beyond, including product approvals, labeling, and supply and distribution agreements
  • Prosecute patents to issuance (more than 30 patent team members have biology or chemistry PhDs), navigate trademarks through the USPTO and health regulatory bodies, and defend patent, trade secret and trademark rights in trial courts and at the USPTO
  • Successful track record of helping life sciences clients avoid — and when necessary resolve —securities class actions, governmental investigations, and disputes with collaboration/licensing partners

To learn more about our life sciences practice, please visit